Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Date:10/24/2011

SEATTLE, Oct. 25, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported its financial results for the third quarter ended September 30, 2011.

"This has been a very exciting quarter for the Company as we move pixantrone one step closer to potential approval in both the U.S. and E.U.," noted James A. Bianco, M.D., CEO of Cell Therapeutics, Inc. "We believe the data contained in the resubmitted NDA confirms the confidence in the efficacy endpoints and also addresses the other requests made by the Food and Drug Administration (the "FDA"). With the day 180 responses regarding our MAA expected this quarter along with the expected reporting of final data on the tosedostat phase II study at the American Society of Hematology's annual meeting, the fourth quarter is shaping up to reflect the solid progress we have made in 2011."

Recent Highlights

  • Resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") for patients who have failed two or more prior lines of therapy.
  • Announced second independent radiology assessment confirmed the statistical robustness of the PIX301 efficacy data.
  • FDA confirmed that the NDA would receive a six month review after resubmission resulting in potential accelerated approval as early as April 2012.
  • Appointed Reed V. Tuckson, M.D., F.A.C.P., to CTI's Board of Directors. Dr. Tuckson is the Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, the Minnesota-based Fortune 25 diversified health care company that employs more than 87,000 people worldwide and serves more than 75 million Americans. Dr. Tuckson oversees the clinically-related programs of the company's six operating businesses and the work of more than 10,000 clinically-related personnel.  
  • Submitted Day 120 response to the European Medicine Agency's (the "EMA") Committee for Medic
    '/>"/>

  • SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
    2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
    3. Cell Therapeutics, Inc. Announces Reverse Stock Split
    4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
    5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
    6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
    7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
    8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
    9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
    10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
    11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
    (Date:10/19/2014)... October 19, 2014 The Latin American ... market in Latin America with analysis and forecast of ... 2013, and is expected to reach $2,366.8 million by ... 2018. , Browse through the TOC of the Latin ... of the in-depth analysis provided. It also provides a ...
    (Date:10/19/2014)... 19, 2014 The Asia-Pacific Bromine ... in Asia-Pacific with analysis and forecast of revenue. ... Pacific Bromine Market report, to get an idea ... a glimpse of the segmentation in the Asia-Pacific ... and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , ...
    (Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar ... Trend and Forecast (2011 - 2016)," analyzes the ... studies the major market drivers, restraints, and opportunities for ... , The global chocolate market is expected to grow ... at an estimated CAGR of 2.7% from 2011 to ...
    Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
    ... Large Well-Known Product and Continues ... of Antibody Therapeutics Pipeline -, BRITISH COLUMBIA, Canada, ... TSX Venture: IXS;, http://www.ixsbio.com ), a drug development company ... Dynamic Cross Linking,(DXL(TM)) technology, announces the development of a ...
    ... reported results for the quarter ended September 30, 2008.,Revenue ... to $112,000 for,the quarter ended September 30, 2007. Revenue ... compared to $715,000 for the nine months,ended September 30, ... quarter of 2008 were,$17.3 million compared to $19.8 million ...
    ... Residual Vascular Risk Reduction: The Global Call to Action, ... Initiative:,R3i, KEY FACTS:, Residual Risk Reduction Initiative (R3i) ... unaddressed by current standards of,care in millions of patients with ... Audubon Room, Ritz Carlton Hotel, 921 Canal Street, New Orleans, ...
    Cached Biology Technology:InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement 2InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement 3Dendreon Reports Third Quarter 2008 Financial Results 2Dendreon Reports Third Quarter 2008 Financial Results 3Dendreon Reports Third Quarter 2008 Financial Results 4Dendreon Reports Third Quarter 2008 Financial Results 5
    (Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
    (Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
    (Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
    Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2
    ... at the University of California, Berkeley, has identified critical ... By manipulating these pathways, the researchers were able to ... its ability to repair and rebuild itself. The ... of the journal EMBO Molecular Medicine , a ...
    ... is well known that people from all over the world ... coral reefs and great fishing. Tourism produces approximately 55 % ... of the total workforce in the Bahamas. However, building of ... come and enjoy the natural beauty of the islands can ...
    ... new study of microscopic marine microbes, called phytoplankton, by ... University of South Carolina has solved a ten-year-old mystery ... ocean. Roughly a decade ago scientists discovered ... matter. Not only were the researchers surprised to find ...
    Cached Biology News:Scientists discover clues to what makes human muscle age 2Scientists discover clues to what makes human muscle age 3Scientists discover clues to what makes human muscle age 4Combining sun, sand and science in the Bahamas 2Combining sun, sand and science in the Bahamas 3Mystery solved: Marine microbe is source of rare nutrient 2Mystery solved: Marine microbe is source of rare nutrient 3
    Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
    ... which is based on a new flow-through technology, ... in situ hybridization of tissues on microscope slide ... study of gene expression, in situ hybridization (ISH) ... can be used to validate and confirm results ...
    ... has been optimized for the analysis of ... software to quickly and accurately locate and ... an ELISA plate or each section of ... been customized to incorporate standard ELISA analysis ...
    ... products feature a dual strength adhesive system which ... use. The adhesives on either side of the ... adheres to the glass has an easy release ... coverslip, forms a stronger bond. This means that ...
    Biology Products: